Cargando…

Tumour immune cell infiltration and survival after platinum-based chemotherapy in high-grade serous ovarian cancer subtypes: A gene expression-based computational study

BACKGROUND: Increasing evidence supports that the immune infiltration of tumours is associated with prognosis. Here, we sought to assess the relevance of the cellular composition of the immune infiltrate to survival after platinum-based chemotherapy amongst patients with high-grade serous ovarian ca...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Rong, Hu, Rong, Zeng, Ying, Zhang, Wei, Zhou, Hong-Hao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Research paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6948169/ https://www.ncbi.nlm.nih.gov/pubmed/31911269 http://dx.doi.org/10.1016/j.ebiom.2019.102602

Ejemplares similares

Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer
por: Wu, Huan, et al.
Publicado: (2019)

Correction to: Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer
por: Wu, Huan, et al.
Publicado: (2020)

Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma
por: Feng, Zheng, et al.
Publicado: (2023)

3468 Predictive biomarkers of platinum-based chemotherapy response in Puerto Rican Hispanics with high-grade serous ovarian cancer.
por: Reyes-Gonzalez, Jeyshka M., et al.
Publicado: (2019)

Expression of hormone receptors predicts survival and platinum sensitivity of high-grade serous ovarian cancer
por: Tan, Jiahong, et al.
Publicado: (2021)

Development and Validation of an Immune-Related Gene-Pair Model of High-Grade Serous Ovarian Cancer After Platinum-Based Chemotherapy
por: Lin, Jiaxing, et al.
Publicado: (2021)

Optimal Time Interval between Neoadjuvant Platinum-Based Chemotherapy and Interval Debulking Surgery in High-Grade Serous Ovarian Cancer
por: Andrikopoulou, Angeliki, et al.
Publicado: (2023)

PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
por: Morgan, Robert D., et al.
Publicado: (2018)

Highly Expressed Progesterone Receptor B Isoform Increases Platinum Sensitivity and Survival of Ovarian High-Grade Serous Carcinoma
por: Lin, Hao, et al.
Publicado: (2021)

MAGE-A10 Protein Expression in Advanced High Grade Serous Ovarian Cancer Is Associated with Resistance to First-Line Platinum-Based Chemotherapy
por: Lisica Šikić, Nataša, et al.
Publicado: (2023)

The peritoneal tumour microenvironment of high-grade serous ovarian cancer
por: Leinster, D Andrew, et al.
Publicado: (2012)

RAD51/geminin/γH2AX immunohistochemical expression predicts platinum-based chemotherapy response in ovarian high-grade serous carcinoma
por: Kim, Kyeongmin, et al.
Publicado: (2023)

Decreased Levels of GSH Are Associated with Platinum Resistance in High-Grade Serous Ovarian Cancer
por: Criscuolo, Daniela, et al.
Publicado: (2022)

Consensus on the management of platinum-sensitive high-grade serous epithelial ovarian cancer in Lebanon
por: Abdallah, Reem, et al.
Publicado: (2023)

Subtyping of high grade serous ovarian carcinoma: histopathological and immunohistochemical approach
por: Khashaba, Marwa, et al.
Publicado: (2022)

Ovarian Carcinosarcoma: Effects of Cytoreductive Status and Platinum-Based Chemotherapy on Survival
por: Jernigan, Amelia M., et al.
Publicado: (2013)

Neutrophil-to-lymphocyte ratio is associated with sensitivity to platinum-based chemotherapy and prognosis in patients with advanced serous ovarian carcinoma
por: Fukuda, Takeshi, et al.
Publicado: (2021)

Glycoproteomics-based signatures for tumor subtyping and clinical outcome prediction of high-grade serous ovarian cancer
por: Pan, Jianbo, et al.
Publicado: (2020)

FXYD5 (Dysadherin) upregulation predicts shorter survival and reveals platinum resistance in high-grade serous ovarian cancer patients
por: Tassi, Renata A., et al.
Publicado: (2019)

Targeting Aurora A Kinase (AAK) in Platinum-Resistant High Grade Serous Ovarian Cancer
por: Ganapathi, Ram N., et al.
Publicado: (2020)

Development of Machine Learning Models to Predict Platinum Sensitivity of High-Grade Serous Ovarian Carcinoma
por: Hwangbo, Suhyun, et al.
Publicado: (2021)

Investigating the effect of optimal cytoreduction in the context of platinum sensitivity in high‐grade serous ovarian cancer
por: Cardillo, Nicholas, et al.
Publicado: (2022)

Combining measures of immune infiltration shows additive effect on survival prediction in high-grade serous ovarian carcinoma
por: Montfort, Anne, et al.
Publicado: (2020)

Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first‐line platinum chemotherapy in high grade serous ovarian cancer
por: Weberpals, Johanne I., et al.
Publicado: (2021)

A chemotherapy response classifier based on support vector machines for high-grade serous ovarian carcinoma
por: Sun, Chao-Yang, et al.
Publicado: (2015)

Classification of Molecular Subtypes of High-Grade Serous Ovarian Cancer by MALDI-Imaging
por: Kassuhn, Wanja, et al.
Publicado: (2021)

Seven Genes Based Novel Signature Predicts Clinical Outcome and Platinum Sensitivity of High Grade IIIc Serous Ovarian Carcinoma
por: Liu, Gang, et al.
Publicado: (2018)

Development of a Genomic Signatures-Based Predictor of Initial Platinum-Resistance in Advanced High-Grade Serous Ovarian Cancer Patients
por: Li, Yuan, et al.
Publicado: (2021)

Stromal infiltrating mast cells identify immunoevasive subtype high-grade serous ovarian cancer with poor prognosis and inferior immunotherapeutic response
por: Cao, Kankan, et al.
Publicado: (2021)

Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy
por: Friedlander, Michael, et al.
Publicado: (2018)

High EMSY expression defines a BRCA‐like subgroup of high‐grade serous ovarian carcinoma with prolonged survival and hypersensitivity to platinum
por: Hollis, Robert L., et al.
Publicado: (2019)

A Qualitative Transcriptional Signature for Predicting Recurrence Risk for High-Grade Serous Ovarian Cancer Patients Treated With Platinum-Taxane Adjuvant Chemotherapy
por: Liu, Yixin, et al.
Publicado: (2019)

Modeling Platinum Sensitive and Resistant High-Grade Serous Ovarian Cancer: Development and Applications of Experimental Systems
por: Cunnea, Paula, et al.
Publicado: (2014)

Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System
por: Wiedemeyer, W. Ruprecht, et al.
Publicado: (2014)

Chloroxine overrides DNA damage tolerance to restore platinum sensitivity in high-grade serous ovarian cancer
por: Silva, Vera L., et al.
Publicado: (2021)

Development of survival predictors for high-grade serous ovarian cancer based on stable radiomic features from computed tomography images
por: Hu, Jiaqi, et al.
Publicado: (2022)

Molecular Abnormalities in Ovarian Cancer Subtypes Other than High-Grade Serous Carcinoma
por: Gilks, C. Blake
Publicado: (2010)

Histopathological subtyping of high-grade serous ovarian cancer using whole slide imaging
por: Miyagawa, Chiho, et al.
Publicado: (2023)

Network vulnerability-based and knowledge-guided identification of microRNA biomarkers indicating platinum resistance in high-grade serous ovarian cancer
por: Qi, Xin, et al.
Publicado: (2019)

Tumour microenvironment‐based molecular profiling reveals ideal candidates for high‐grade serous ovarian cancer immunotherapy
por: Lu, Xiaofan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ospakruamv71jqq5u8v6ama91g